Effects of microbiota on anticancer drugs: Current knowledge and potential applications

Huang, Jiayuan; Liu, Wenting; Kang, Wanying; He, Yulong; Yang, Ruifu; Mou, Xiangyu; Zhao, Wenjing

doi:10.1016/j.ebiom.2022.104197

Cited by 41 publications

(23 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the complex interaction between antibiotic treatment, anti-cancer drugs and the microbiome in modulating the anti-cancer response (reviewed in Ref. [3]), we, however, agree with our colleagues that further analyses are required to clarify differences in the role of antibiotic treatment between radiotherapy, chemoradiation and cetuximabbased bioradiotherapy (and maybe in future, (chemo)radiation plus immune checkpoint inhibitors).…”

supporting

confidence: 61%

Authors’ response to the Letter to the Editor by Efsun Somay and Erkan Topkan regarding our study “The influence of antibiotic administration on the outcomes of head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiation”

Rühle

Zou

Popp

et al. 2023

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

supporting

confidence: 61%

Authors’ response to the Letter to the Editor by Efsun Somay and Erkan Topkan regarding our study “The influence of antibiotic administration on the outcomes of head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiation”

Rühle

Zou

Popp

et al. 2023

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

“…The impact of microbiota, especially the gut microbiota, on the modulation of cancer treatment and the susceptibility to side effects has been addressed [ 24 , 107 ] Pharmacomicrobiomics has arisen to exploit drug-microbiota interactions in anticancer therapies [ 108 , 109 ].…”

Section: The Interplay Between Microbiota and Cancer Treatmentmentioning

confidence: 99%

“…The following topics will address the interplay of microbiota and cancer treatments, e.g., surgery, chemotherapy, radiotherapy, and immunotherapy ( Figure 4 ) [ 84 , 107 , 109 , 110 ], addressing aerodigestive and digestive cancers.…”

Section: The Interplay Between Microbiota and Cancer Treatmentmentioning

confidence: 99%

The Debate between the Human Microbiota and Immune System in Treating Aerodigestive and Digestive Tract Cancers: A Review

et al. 2023

View full text Add to dashboard Cite

The human microbiota comprises a group of microorganisms co-existing in the human body. Unbalanced microbiota homeostasis may impact metabolic and immune system regulation, shrinking the edge between health and disease. Recently, the microbiota has been considered a prominent extrinsic/intrinsic element of cancer development and a promising milestone in the modulation of conventional cancer treatments. Particularly, the oral cavity represents a yin-and-yang target site for microorganisms that can promote human health or contribute to oral cancer development, such as Fusobacterium nucleatum. Moreover, Helicobacter pylori has also been implicated in esophageal and stomach cancers, and decreased butyrate-producing bacteria, such as Lachnospiraceae spp. and Ruminococcaceae, have demonstrated a protective role in the development of colorectal cancer. Interestingly, prebiotics, e.g., polyphenols, probiotics (Faecalibacterium, Bifidobacterium, Lactobacillus, and Burkholderia), postbiotics (inosine, butyrate, and propionate), and innovative nanomedicines can modulate antitumor immunity, circumventing resistance to conventional treatments and could complement existing therapies. Therefore, this manuscript delivers a holistic perspective on the interaction between human microbiota and cancer development and treatment, particularly in aerodigestive and digestive cancers, focusing on applying prebiotics, probiotics, and nanomedicines to overcome some challenges in treating cancer.

show abstract

“…Indeed, the GM is increasingly seen as important and modifiable aspect of anticancer therapeutic response. [5, 6]We hypothesized that gut microbiome composition has a positive influence on cancer therapy in bladder cancer. To test this hypothesis, we prospectively collected fecal microbiome samples from patients with MIBC starting treatment with either GC or ddMVAC across two American institutions.…”

Section: Introductionmentioning

confidence: 99%

Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-Institutional Prospective Cohort Evaluation

Bukavina

Ginwala

Sindhani

et al. 2023

Preprint

View full text Add to dashboard Cite

Treatment with neoadjuvant chemotherapy (NAC) in muscle invasive bladder cancer (MIBC) is associated with clinical benefit in urothelial carcinoma. While extensive research evaluating role of tumor mutational expression profiles and clinicopathologic factors into chemoresponse has been published, the role of gut microbiome (GM) in bladder cancer in chemoresponse has not been thoroughly evaluated. A working knowledge of the microbiome and its effect on all forms of cancer therapy in BC is critical. Here we examine gut microbiome of bladder cancer patients undergoing NAC. Overall, there was no significant difference in alpha and beta diversity by responder status. However, analysis of fecal microbiome samples showed that a higher abundance of Bacteroides within both institutional cohorts during NAC was associated with residual disease at the time of radical cystectomy regardless of chemotherapy regimen. Group community analysis revealed presence of favorable microbial subtypes in complete responders. Finally, fecal microbial composition outperformed clinical variables in prediction of complete response (AUC 0.88 vs AUC 0.50), however, no single microbial species could be regarded as a fully consistent biomarker. Microbiome-based community signature as compared to single microbial species is more likely to be associated as the link between bacterial composition and NAC response.

show abstract

Effects of microbiota on anticancer drugs: Current knowledge and potential applications

Cited by 41 publications

References 76 publications

Authors’ response to the Letter to the Editor by Efsun Somay and Erkan Topkan regarding our study “The influence of antibiotic administration on the outcomes of head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiation”

Authors’ response to the Letter to the Editor by Efsun Somay and Erkan Topkan regarding our study “The influence of antibiotic administration on the outcomes of head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiation”

The Debate between the Human Microbiota and Immune System in Treating Aerodigestive and Digestive Tract Cancers: A Review

Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-Institutional Prospective Cohort Evaluation

Contact Info

Product

Resources

About